Lancet Microbe最新文献

{"title":"Are we overlooking the obvious? Bacterial evolution is at the heart of antimicrobial resistance","authors":"Dennis Nurjadi , Hinrich Schulenburg , Stefan Niemann , Annelies S Zinkernagel , Jan Rupp","doi":"10.1016/j.lanmic.2024.101069","DOIUrl":"10.1016/j.lanmic.2024.101069","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"6 5","pages":"Article 101069"},"PeriodicalIF":20.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishing the lowest penicillin concentration to prevent pharyngitis due to Streptococcus pyogenes using a human challenge model (CHIPS): a randomised, double-blind, placebo-controlled trial","authors":"Thel K Hla MBBS ,&nbsp;Joshua Osowicki PhD ,&nbsp;Julie A Marsh PhD ,&nbsp;Sam Salman PhD ,&nbsp;Madhu Page-Sharp PhD ,&nbsp;Okhee Yoo PhD ,&nbsp;Kristy Azzopardi BSc ,&nbsp;Michael Morici Bsc ,&nbsp;Prof Kevin T Batty PhD ,&nbsp;Renae K Barr PhD ,&nbsp;Stephanie L Enkel MPH ,&nbsp;Joseph Kado PhD ,&nbsp;Lara Hatchuel PhD ,&nbsp;Alma Fulurija PhD ,&nbsp;Prof James S McCarthy PhD ,&nbsp;Prof Thomas L Snelling PhD ,&nbsp;Prof Andrew C Steer PhD ,&nbsp;Prof Jonathan Carapetis PhD ,&nbsp;Prof Laurens Manning PhD","doi":"10.1016/j.lanmic.2024.101038","DOIUrl":"10.1016/j.lanmic.2024.101038","url":null,"abstract":"<div><h3>Background</h3><div>The in-vivo plasma concentration of penicillin needed to prevent <em>Streptococcus pyogenes</em> pharyngitis, recurrent acute rheumatic fever, and progressive rheumatic heart disease is not known. We used a human challenge model to assess the minimum penicillin concentration required to prevent streptococcal pharyngitis.</div></div><div><h3>Methods</h3><div>In CHIPS, a randomised, double-blind, placebo-controlled, human challenge trial, healthy adult volunteers were randomly assigned by a computer-generated random sequence to target steady-state penicillin plasma concentrations (placebo, 3, 6, 9, 12, or 20 ng/mL). The study was a single-centre trial held in Perth, WA, Australia. Participants had to be healthy adults, aged 18–40 years, at low risk of complicated <em>S pyogenes</em> disease, and without high type-specific IgG antibodies against the <em>emm</em>75 <em>S pyogenes</em> challenge strain. Participants and staff involved in clinical care remained masked to treatment allocation for the duration of the study. Individualised 5-day continuous intravenous infusions of penicillin were commenced 12 h before direct pharyngeal application of the <em>emm</em>75 challenge strain. The primary endpoint was clinical pharyngitis. This trial is registered on the Australian New Zealand Clinical Trials Registry, ACTRN12621000751875, and is completed.</div></div><div><h3>Findings</h3><div>Between Aug 23, 2022, and July 31, 2023, 60 participants were randomly assigned (35 [58%] were female and 25 [42%] were male), with 57 included in the analysis. The clinical pharyngitis endpoint was met in eight (57%) of 14 in the placebo group, four (44%) of nine in the 3 ng/mL target steady-state penicillin plasma concentration group, four (44%) of nine in the 6 ng/mL group, none of eight in the 9 ng/mL group, none of eight in the 12 ng/mL group, and none of nine in the 20 ng/mL group. No severe or serious adverse events occurred. Using Bayesian concentration–response modelling, the minimum steady-state plasma concentration of penicillin for which 90% of participants would avoid clinical pharyngitis was 8·1 ng/mL (95% credible interval 6·1–10·9).</div></div><div><h3>Interpretation</h3><div>When steady-state penicillin concentrations are greater than 9 ng/mL, few people will develop experimental <em>emm</em>75 <em>S pyogenes</em> pharyngitis. These data will inform efforts to improve long-acting penicillin preparations and dosage regimens to prevent recurrent rheumatic fever and rheumatic heart disease.</div></div><div><h3>Funding</h3><div>The National Health and Medical Research Council of Australia.</div></div>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"6 5","pages":"Article 101038"},"PeriodicalIF":20.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143744213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between HIV-1 Nef-mediated MHC-I downregulation and the maintenance of the replication-competent latent viral reservoir in individuals with virally suppressed HIV-1 in Uganda: an exploratory cohort study","authors":"Mitchell J Mumby PhD ,&nbsp;Jessica L Prodger PhD ,&nbsp;Jada Hackman PhD ,&nbsp;Sharada Saraf BS ,&nbsp;Xianming Zhu MHS ,&nbsp;Roux-Cil Ferreira PhD ,&nbsp;Stephen Tomusange Dipl ,&nbsp;Samiri Jamiru BMLSc ,&nbsp;Aggrey Anok MS ,&nbsp;Taddeo Kityamuweesi BBLT ,&nbsp;Paul Buule BMLSc ,&nbsp;Corby Fink PhD ,&nbsp;Cassandra R Edgar BMSc ,&nbsp;Steven M Trothen PhD ,&nbsp;Prof Gregory A Dekaban PhD ,&nbsp;Erin E Brown BS ,&nbsp;Adam A Capoferri PhD ,&nbsp;Owen R Baker BS ,&nbsp;Ethan Klock MPH ,&nbsp;Jernelle C Miller MS ,&nbsp;Prof Jimmy D Dikeakos PhD","doi":"10.1016/j.lanmic.2024.101018","DOIUrl":"10.1016/j.lanmic.2024.101018","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;The persistence of a replication-competent latent viral reservoir (RC-LVR) during antiretroviral therapy (ART) is a barrier to the development of a cure for HIV-1, but the role of viral genes in influencing RC-LVR size is unclear. We aimed to assess whether the magnitude by which the HIV-1 accessory protein Nef evades the adaptive immune response by downregulating MHC-I or CD4, or both, from the surface of infected cells is associated with the rate at which the RC-LVR in people with HIV-1 changes during long-term ART (&gt;1 year).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;We conducted an exploratory cohort study in which &lt;em&gt;nef&lt;/em&gt; genes were sequenced from outgrowth viruses derived from the quantitative viral outgrowth assay (QVOA) for a group of people with ART-suppressed HIV-1 in Uganda between 2015 and 2020. Study participants were selected from the Rakai Health Sciences Program (RHSP) LVR cohort, a cohort of 90 adults (aged ≥18 years) who were HIV-1 positive, receiving ART, and had maintained viral suppression for at least 1 year at the time of study enrolment. For this study, participants were required to have available p24&lt;sup&gt;+&lt;/sup&gt; QVOA wells that contained a single viral outgrowth isolate, as assessed by next-generation sequencing. In cases where further sequencing identified wells containing multiple viral clones, all sequenced &lt;em&gt;nef&lt;/em&gt; variants were included for functional analysis. The unique isolated &lt;em&gt;nef&lt;/em&gt; variants were used to generate pseudoviruses, which were employed to measure cell surface CD4 and MHC-I downregulation in infected CD4&lt;sup&gt;+&lt;/sup&gt; Sup-T1 cells via flow cytometry. The size and rate of change of the RC-LVR in participants was estimated using previous QVOA results and a Bayesian model. We then assessed whether a correlation existed between the extent to which the Nef proteins downregulated cell surface MHC-I and CD4 and the calculated RC-LVR rate of change during the study period.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;14 (15%) of 90 participants from the RHSP cohort met the inclusion criteria and were enrolled in this study. 49 &lt;em&gt;nef&lt;/em&gt; sequences were isolated from these participants. We observed variability in participant-derived Nef-mediated cell surface MHC-I downregulation (median 114·88% [IQR 104·93–121·51] of the downregulation capacity of NL4-3 Nef) and CD4 downregulation (94·50% [84·05–100·16] of NL4-3 Nef). The estimated rate of change of the RC-LVR was positive for four participants. For one donor, the rate of change was significantly positive (7·4 × 10&lt;sup&gt;–4&lt;/sup&gt; logit infectious units per million [IUPM] per day [95% credibility interval 3·2 × 10&lt;sup&gt;–4&lt;/sup&gt; to 1·2 × 10&lt;sup&gt;–3&lt;/sup&gt;]) over the course of the study period (2015–20). The estimated rate of change of the RC-LVR for the remaining ten participants was negative, and significantly negative in four donors (–1·1 × 10&lt;sup&gt;–3&lt;/sup&gt; logit IUPM per day [95% credibility interval –1·8 × 10&lt;sup&gt;–3&lt;/sup&gt; to –3·7 ","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"6 5","pages":"Article 101018"},"PeriodicalIF":20.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Our first 5 years: from pandemic to political turmoil","authors":"The Lancet Microbe","doi":"10.1016/j.lanmic.2025.101148","DOIUrl":"10.1016/j.lanmic.2025.101148","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"6 5","pages":"Article 101148"},"PeriodicalIF":20.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143916399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paying more attention to HIV-1 recombinants among men who have sex with men–Author’s reply","authors":"Joris Hemelaar ,&nbsp;Malavika Nair ,&nbsp;Lucy Gettins ,&nbsp;Shona Kirtley","doi":"10.1016/j.lanmic.2024.101059","DOIUrl":"10.1016/j.lanmic.2024.101059","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"6 5","pages":"Article 101059"},"PeriodicalIF":20.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143013677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and immunogenicity of a bivalent Ebola virus and Sudan virus ChAdOx1 vectored vaccine in adults in the UK: an open-label, non-randomised, first-in-human, phase 1 clinical trial","authors":"Daniel Jenkin MRCP ,&nbsp;Rebecca Makinson MBiol ,&nbsp;Helen Sanders BSc ,&nbsp;Alexander Sampson VetMB ,&nbsp;Abigail Platt BN ,&nbsp;Nguyen Tran PhD ,&nbsp;Tanya Dinesh MSci ,&nbsp;Reece Mabbett BSc ,&nbsp;Alison Lawrie PhD ,&nbsp;Jack Quaddy BA ,&nbsp;Ian Poulton DipHE ,&nbsp;Eleanor Berrie PhD ,&nbsp;Paola Cicconi PhD ,&nbsp;Prof Teresa Lambe PhD","doi":"10.1016/j.lanmic.2024.101022","DOIUrl":"10.1016/j.lanmic.2024.101022","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Four &lt;em&gt;Orthoebolavirus&lt;/em&gt; species can cause Ebola disease, with Ebola virus (species &lt;em&gt;Orthoebolavirus zairense&lt;/em&gt;) and Sudan virus (species &lt;em&gt;Orthoebolavirus sudanense&lt;/em&gt;) responsible for the majority of outbreaks and cases. No vaccines have been approved against orthoebolaviruses other than Ebola virus. We aimed to evaluate the safety and immunogenicity of a non-replicating single-adenoviral vaccine (ChAdOx1 biEBOV) encoding both Ebola virus and Sudan virus glycoproteins.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;In this open-label, non-randomised, first-in-human, phase 1, dose-escalation clinical trial of ChAdOx1 biEBOV, participants aged 18–55 years without clinically significant medical comorbidities or previous adenovirus vaccine exposure were recruited at a single site (Oxford, UK). Participants were non-randomly enrolled to a low-dose group (5 × 10⁹ viral particles [vp] of ChAdOx1 biEBOV), a medium-dose group (2·5 × 10&lt;sup&gt;1&lt;/sup&gt;⁰ vp), and a high-dose group (5 × 10&lt;sup&gt;1&lt;/sup&gt;⁰ vp). All doses were administered intramuscularly. After recruitment of all participants, the protocol was amended so that a subgroup from the high-dose group received a second high dose of vaccine 12 weeks after the first dose. Primary outcome measures were assessment of solicited adverse events for 7 days after vaccinations, unsolicited adverse events for 28 days after vaccinations, changes in clinical laboratory measures within 28 days after vaccination, and serious adverse events and adverse events of special interest for the study duration. Secondary outcomes were assessment of humoral and cellular immunity to Ebola virus and Sudan virus glycoprotein. This study is registered with &lt;span&gt;&lt;span&gt;ClinicalTrials.gov&lt;/span&gt;&lt;svg&gt;&lt;path&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;, &lt;span&gt;&lt;span&gt;NCT05079750&lt;/span&gt;&lt;svg&gt;&lt;path&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;Between Nov 11, 2021, and April 7, 2022, 40 individuals attended the trial screening visit, of whom 26 were enrolled (six in the low-dose group, six in the medium-dose group, and 14 in the high-dose group). Seven participants in the high-dose group received one vaccine dose and seven received two vaccine doses. Local solicited adverse events were reported by 17 (65%) of 26 participants after dose 1 and five (71%) of seven after dose 2. Systemic solicited adverse events were reported by 23 (88%) participants after dose 1 and five (71%) after dose 2. All solicited adverse events were mild or moderate, with no severe events reported. No serious adverse reactions were reported. Unsolicited adverse events related to vaccination were mostly mild or moderate and short-lived, such as joint pain or upper respiratory symptoms. One adverse event of special interest, thrombocytopenia, occurred transiently in one participant in the high-dose group. Rapidly resolving lymphopenia was common at the early post-vaccination timepoint. A single 5 × 10&lt;sup&gt;1&lt;/sup&gt;⁰ vp dose vaccination elicited seropos","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"6 5","pages":"Article 101022"},"PeriodicalIF":20.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of inflammatory markers with post-acute clinical findings among survivors of Ebola virus disease with and without viral RNA shedding in the semen in Liberia: a nested case–control study","authors":"Mosoka P Fallah PhD ,&nbsp;Collin Van Ryn MS ,&nbsp;J Soka Moses MD ,&nbsp;Moses Badio MS ,&nbsp;Tamba Fayiah BSc ,&nbsp;Kumblytee Johnson MD ,&nbsp;Dehkontee Gayedyu-Dennis MD ,&nbsp;Allen O Eghrari MD ,&nbsp;Sheri D Weiser MD ,&nbsp;Prof Travis C Porco PhD ,&nbsp;Prof Jeffrey N Martin MD ,&nbsp;Michael J Peluso MD ,&nbsp;David R McIlwain PhD ,&nbsp;Bonnie Dighero-Kemp BS ,&nbsp;Elizabeth Higgs MD ,&nbsp;Lisa E Hensley PhD ,&nbsp;George W Rutherford MD ,&nbsp;Prof Cavan Reilly PhD ,&nbsp;J Daniel Kelly MD PhD","doi":"10.1016/j.lanmic.2024.101033","DOIUrl":"10.1016/j.lanmic.2024.101033","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;A high proportion of survivors of Ebola virus disease (EVD) have post-acute sequelae of EVD (PASE), but the relationship between inflammation and PASE pathogenesis is poorly understood. This study tests the hypothesis that inflammation is associated with PASE among survivors with and without viral RNA shedding in the semen.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;This was a case–control study nested in a longitudinal cohort that recruited confirmed survivors of EVD and their uninfected contacts from the 2013–16 EVD epidemic in Liberia, starting on June 1, 2015. We included participants aged at least 18 years with clinical data and plasma available at cohort baseline for analysis. A semen donation substudy tested male survivors for Ebola virus RNA shedding in the semen. A sex-stratified and survivor-stratified random sample of cases (survivors) and controls (contacts) was obtained to select stored baseline plasma samples for cytokine testing of markers of inflammation, immune regulation, and antiviral responses. Serostatus of cases and controls was confirmed by Filovirus Animal Nonclinical Group assay. We identified inflammatory markers (adjusted p≤0·05) elevated in cases compared with controls and then used these biomarkers in analyses comparing survivors with and without pre-specified PASE-associated clinical findings (self-reported symptoms and abnormal examination findings). Survivors with viral RNA shedding in the semen formed subgroup analyses.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;Our analysis cohort consisted of 1044 participants (594 survivors of EVD and 450 uninfected contacts); 515 (49·3%) were female and 529 (50·7%) were male. The subcohort of 243 male survivors with data on viral shedding included 81 (33%) participants with viral shedding in semen. Median time from acute EVD to baseline was 317 days (IQR 271–366). Survivors of EVD showed a pattern of elevated inflammatory markers indicative of macrophage (MCP-1, IL-1β, and M-CSF) and angiogenic factor activation (VEGF-A) compared with controls (adjusted p&lt;0·05). In survivors with viral shedding in the semen compared with controls, VEGF-A was the only inflammatory marker that was significantly higher (adjusted p&lt;0·001). After restricting the analysis to survivors, each inflammatory marker had a specific pattern of clinical findings. Higher levels of IL-1β were associated with higher odds of urinary frequency (p=0·002), musculoskeletal abnormalities (p=0·003), and abdominal abnormalities (p=0·03). By contrast, higher levels of MCP-1 were associated with lower odds of the same clinical findings. M-CSF was the only inflammatory marker associated with lower odds of joint pain (p=0·04). Higher levels of VEGF-A were associated with higher odds of abnormal chest findings in the overall survivor group (p=0·02) and in the subgroup with viral shedding in the semen (p=0·02).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Interpretation&lt;/h3&gt;&lt;div&gt;We found evidence of distinct biological pathwa","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"6 5","pages":"Article 101033"},"PeriodicalIF":20.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143626442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Marburg virus outbreak in Tanzania","authors":"Priya Venkatesan","doi":"10.1016/j.lanmic.2025.101121","DOIUrl":"10.1016/j.lanmic.2025.101121","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"6 5","pages":"Article 101121"},"PeriodicalIF":20.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143626443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WHO launches Technical Brief for encephalitis","authors":"Timothy Jesudason","doi":"10.1016/j.lanmic.2025.101129","DOIUrl":"10.1016/j.lanmic.2025.101129","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"6 5","pages":"Article 101129"},"PeriodicalIF":20.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing mucosal immunity induced by type 2 oral poliovirus vaccines.","authors":"Kimberly M Thompson","doi":"10.1016/j.lanmic.2025.101104","DOIUrl":"https://doi.org/10.1016/j.lanmic.2025.101104","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":" ","pages":"101104"},"PeriodicalIF":20.9,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143990258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}